Your browser is no longer supported. Please, upgrade your browser.
Settings
AGN Allergan plc daily Stock Chart
AGN [NYSE]
Allergan plc
IndexS&P 500 P/E- EPS (ttm)-12.48 Insider Own0.10% Shs Outstand333.45M Perf Week0.78%
Market Cap54.70B Forward P/E9.89 EPS next Y16.59 Insider Trans-13.71% Shs Float331.73M Perf Month-8.68%
Income-4001.00M PEG- EPS next Q3.38 Inst Own90.60% Short Float2.60% Perf Quarter-5.21%
Sales15.94B P/S3.43 EPS this Y63.30% Inst Trans6.11% Short Ratio2.79 Perf Half Y-27.02%
Book/sh198.59 P/B0.83 EPS next Y6.47% ROA9.30% Target Price218.81 Perf Year-33.57%
Cash/sh16.32 P/C10.05 EPS next 5Y7.41% ROE16.80% 52W Range156.00 - 256.80 Perf YTD0.28%
Dividend2.88 P/FCF214.76 EPS past 5Y-28.70% ROI0.10% 52W High-36.12% Beta1.24
Dividend %1.76% Quick Ratio1.10 Sales past 5Y26.00% Gross Margin86.40% 52W Low5.15% ATR5.99
Employees16700 Current Ratio1.20 Sales Q/Q11.40% Oper. Margin-32.10% RSI (14)40.27 Volatility3.97% 3.56%
OptionableYes Debt/Eq0.46 EPS Q/Q-948.20% Profit Margin73.10% Rel Volume0.86 Prev Close164.47
ShortableYes LT Debt/Eq0.40 EarningsFeb 06 BMO Payout5.00% Avg Volume3.10M Price164.04
Recom2.10 SMA20-6.38% SMA50-4.80% SMA200-20.63% Volume2,652,329 Change-0.26%
Feb-07-18Reiterated Leerink Partners Outperform $237 → $242
Dec-07-17Downgrade Argus Buy → Hold
Nov-29-17Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-27-17Resumed Leerink Partners Outperform $237
Nov-02-17Reiterated RBC Capital Mkts Outperform $250 → $221
Oct-19-17Reiterated RBC Capital Mkts Outperform $277 → $250
Oct-17-17Reiterated UBS Buy $275 → $255
Oct-02-17Reiterated Barclays Equal Weight
Sep-25-17Reiterated RBC Capital Mkts Outperform $285 → $277
Sep-20-17Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-16-17Initiated Cantor Fitzgerald Neutral $231
Jun-09-17Reiterated Mizuho Buy $275 → $267
May-10-17Reiterated RBC Capital Mkts Outperform $279 → $284
May-10-17Downgrade Goldman Buy → Neutral
Feb-09-17Reiterated Mizuho Buy $273 → $275
Dec-09-16Reiterated Credit Suisse Outperform $301 → $274
Nov-17-16Reiterated Mizuho Buy $293 → $273
Nov-03-16Reiterated RBC Capital Mkts Outperform $300 → $279
Nov-01-16Reiterated Mizuho Buy $299 → $293
Oct-31-16Resumed Barclays Equal Weight $250
Feb-16-18 07:01PM  Jim Cramer: Drug Stocks on the Move TheStreet.com
06:58PM  Allergan Presents Data at the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego PR Newswire
05:48PM  Allergan PLC (AGN) Files 10-K for the Fiscal Year Ended on December 31, 2017 GuruFocus.com
03:31PM  United Therapeutics reaches patent settlement with Actavis American City Business Journals
03:16PM  United Therapeutics settles patent litigation over $157M drug American City Business Journals
08:44AM  Ironwood (IRWD) Beats Estimates in Q4 Earnings, Stock Up Zacks
06:04AM  Why in the World Does Warren Buffett Like Teva Pharmaceutical? Motley Fool
Feb-15-18 07:47PM  Allergan Exec on Medical Aesthetics: 'The Future Is About Market Expansion' TheStreet.com
Feb-14-18 08:02AM  How Confident Are Insiders About Allergan And More? Simply Wall St.
Feb-13-18 06:22PM  Jerome Dodson Comments on Allergan GuruFocus.com
06:14PM  Jerome Dodson's Parnassus Fund 4th Quarter Commentary GuruFocus.com
Feb-11-18 11:57PM  [$$] New Tax Law Haunts Companies That Did Inversion Deals The Wall Street Journal
09:54AM  Stocks That Fell to 3-Year Lows in the Week of Feb. 9 GuruFocus.com
07:00AM  New Tax Law Haunts Companies That Did Inversion Deals The Wall Street Journal
Feb-10-18 05:36PM  OxyContin maker will stop promoting opioids to doctors Associated Press
Feb-09-18 09:50AM  Teva (TEVA) Q4 Earnings Top, Stock Tanks on Weak 2018 View Zacks
08:00AM  Allergan Declares First Quarter 2018 Cash Dividend of $0.72 Per Ordinary Share and Provides Annual General Meeting of Shareholders Updates PR Newswire
Feb-08-18 09:41AM  The Alzheimer's Drug Pipeline: High Failure Rates In Research On An Increasingly Common Disease Benzinga
04:36AM  Array BioPharma and Allergan Just Scored Big On Phase III Data Market Exclusive
Feb-06-18 05:30PM  Allergan Pops On Consensus-Topping Quarter, Strong Migraine Trial Investor's Business Daily
04:48PM  Centene, LabCorp Among Healthcare Stock Gainers TheStreet.com
04:19PM  Dow Finishes With Gain of 567 Points; S&P 500 and Nasdaq Also Close Higher TheStreet.com
12:20PM  Allergan CEO: We Are Staying in Ireland TheStreet.com
12:16PM  Lululemon CEO resigns, GM up on earnings, and Allergan's forecast disappoints Yahoo Finance
11:59AM  Lulu CEO departs, GM up after earnings, Allergan's forecast disappoints Yahoo Finance Video
11:20AM  Charts of the Day: Lululemon, GM, Allergan Yahoo Finance Video
10:30AM  Allergan (AGN) Q4 Earnings Beat on Increase in Botox Sales Zacks
10:24AM  Allergan's profit beats; migraine drug succeeds in key study Reuters
10:22AM  Stocks to Watch: Boeing, Netflix, GM, Lululemon, Micron, Skyworks, Pfizer, ADM The Wall Street Journal
08:50AM  Allergan's profit beats; migraine drug succeeds in key study Reuters
08:40AM  Allergan (AGN) Beats Q4 Earnings & Sales, Stock Up Zacks
08:19AM  A Regular Winning Trade Becomes Roadkill in Market Meltdown TheStreet.com
07:28AM  Allergan shares rise after Q4 profit, revenue beats MarketWatch
07:06AM  Allergan shares surge after positive late-stage migraine drug results MarketWatch
07:02AM  Allergan smashes earnings estimates, says a trial for its migraine drug succeeds CNBC
07:00AM  Allergan Reports Solid Finish to 2017 with 12% Increase in Fourth Quarter GAAP Net Revenues to $4.3 Billion PR Newswire
06:50AM  Allergan plc to Host Earnings Call ACCESSWIRE
06:45AM  Allergan Announces Positive Top Line Phase 3 Results for Ubrogepant - an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine PR Newswire
Feb-05-18 09:17AM  [$$] Allergan Names Matthew Walsh New Finance Chief The Wall Street Journal
08:03AM  Allergan names current Catalent CFO as its CFO MarketWatch
07:51AM  Matthew M. Walsh Appointed Executive Vice President and Chief Financial Officer of Allergan plc PR Newswire
07:40AM  Allergan's Pipeline Matters More Than Its Earnings Do: RBC TheStreet.com
Feb-02-18 05:22PM  Arnold Van Den Berg Fuels Prem Watsa's Fairfax India in 4th Quarter GuruFocus.com
03:06PM  Allergan completes restructuring, pushes hard in China Reuters
01:16PM  Teva Completes Sale of Women's Health Segment for $703M Zacks
12:48PM  Teva Is Playing Debt Roulette and It May Just Work GuruFocus.com
10:42AM  Allergan's Anti-Infective Drug Avycaz Receives Third FDA Nod Zacks
Feb-01-18 04:31PM  FDA Approves AVYCAZ® (ceftazidime and avibactam) for the Treatment of Patients with Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia PR Newswire
04:30PM  FDA approves Allergan's Avycaz for two types of pneumonia Reuters
02:19PM  Vanguard Health Care Fund Buys Danaher, CVS Health, Adds to Allergan GuruFocus.com
10:42AM  Allergan (AGN) to Report Q4 Earnings: What's in the Cards? Zacks
08:49AM  Allergan to pay Israel's Teva Pharm $700 million to settle dispute Reuters
08:24AM  Allergan will pay Teva $700 mln to settle dispute MarketWatch
07:55AM  New Research: Key Drivers of Growth for Guess?, Acer Therapeutics, American National Insurance, J P Morgan Chase, Juno Therapeutics, and Allergan Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Jan-31-18 04:15PM  Allergan to Present at The Leerink Partners 7th Annual Global Healthcare Conference PR Newswire
07:31AM  Allergan Introduces "Not Cool vs. Cool" Multi-Channel Campaign for CoolSculpting® and Professional Athlete Brand Ambassadors: Figure Skater Johnny Weir and Golfer Ian Poulter PR Newswire
Jan-30-18 12:58PM  Analysts Take Action on Healthcare Stocks GuruFocus.com
09:17AM  Allergan CEO: Wonderful to see how Bezos, Buffett and Dim... CNBC Videos
Jan-29-18 05:58PM  Rivals Unlikely to Knock Allergan's Botox Off its Perch: Analyst TheStreet.com
03:02PM  Is Allergan plc (NYSE:AGN) Undervalued? Simply Wall St.
10:39AM  Barclays Injects Allergan With An Upgrade, Says Valuation Model Has Improved Benzinga
10:00AM  Pernix Therapeutics Holdings Inc Reaches Settlement in Zohydro Patent Litigation SmarterAnalyst
Jan-26-18 09:02AM  Pfizers 4Q17 Estimates: Products with Lower Sales Market Realist
09:00AM  What to Expect for Novartiss Subsidiary Alcon in 2018 Market Realist
08:17AM  New York City Sues Big Pharma For Opioid Epidemic, But Does The Lawsuit Make Sense? Market Exclusive
Jan-25-18 11:55AM  Analysts Take Action on Healthcare Stocks GuruFocus.com
07:30AM  Allergan's Botox Business Could Stave Off Competition by Inking This Deal: RBC TheStreet.com
Jan-24-18 05:17PM  Wally Weitz Comments on Allergan GuruFocus.com
04:35PM  Value Investor Wally Weitz Buys Amazon GuruFocus.com
Jan-23-18 01:22PM  When to Buy Stock in Nvidia, Allergan and Tesla: Must-See Charts TheStreet.com
10:48AM  Amgen's Migraine Drug Hits Primary Endpoint in Phase IIIb Zacks
07:34AM  Teva's Asthma Therapy Reslizumab Fails in Late-Stage Studies Zacks
Jan-22-18 09:08AM  Big pharma on a buying spree as Celgene buys Juno and San... CNBC Videos
09:01AM  Merck & Co.s Animal Health Business in 3Q17 Market Realist
08:17AM  Whom Will Pfizer Buy in 2018? Motley Fool
Jan-19-18 12:11PM  Why this East Bay drug maker's stock price nearly doubled last year American City Business Journals
10:34AM  Amgen/Allergan's Avastin Biosimilar Secures EU Approval Zacks
09:35AM  Johnson & Johnsons Revenue Estimates for 4Q17 Market Realist
Jan-18-18 04:00PM  European Commission Approves Amgen And Allergan's MVASI® (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer PR Newswire
09:01AM  How Amgens Biosimilars Are Positioned for 2018 Market Realist
06:20AM  Allergan Could Raise $1 Billion From Anti-Infectives Sale - RBC Capital Markets TheStreet.com
Jan-17-18 02:53PM  Allergan Needs More Time to Make a Proper Bottom TheStreet.com
11:59AM  Polaris Global Value Fund 4th Quarter Shareholder Letter GuruFocus.com
10:49AM  Judge approves settlement between Allergan shareholders and Ackman American City Business Journals
12:14AM  [$$] Judge Signals He Will Approve $290 Million Settlement Between Allergan Shareholders and Pershing, Valeant The Wall Street Journal
Jan-16-18 06:02PM  [$$] Judge Signals He Will Approve Settlement Between Allergan Shareholders and Pershing, Valeant The Wall Street Journal
04:59PM  Imprimis receives FDA warning over eye medication advertising Reuters
10:02AM  Teva's Trisenox Gets FDA Approval as First-Line Treatment Zacks
08:30AM  Ironwood and Allergan Announce Settlement with Sun Pharma Resolving LINZESS® (linaclotide) Patent Litigation Business Wire
Jan-12-18 06:29PM  1st trial date set in state lawsuit over opioid epidemic Associated Press
07:00AM  Concerns About Allergan's Health Are Overblown Morningstar
Jan-11-18 09:00PM  Changes to Federal Tax Law Just What the Doctor Ordered for Healthcare Firms TheStreet.com
03:33PM  Ackmans Pershing Square cuts hedge-fund fees due to lawsuit settlement MarketWatch
12:56PM  Pershing Square lowering management fees CNBC Videos
Jan-10-18 04:55PM  What Analysts Recommend for Teva Pharmaceuticals Market Realist
12:19PM  3 Reasons Allergan Is Set Up for Success in 2018 TheStreet.com
07:55AM  Treasury Bond Yield Pushes Ahead of the S&P 500 InvestorPlace
Jan-09-18 05:20PM  Stocks Set for Record Run as Risks Multiply InvestorPlace
04:09PM  Judge urges action on '100 percent manmade' opioid crisis Associated Press
01:24PM  U.S. pharma executives expect deals to pick up after tax overhaul Reuters
Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, the company distributes generic and branded pharmaceutical products primarily to independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics, and physician offices. Further, it develops a portfolio of breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. The company has licensing agreement with Assembly Biosciences, Inc.; Mimetogen Pharmaceuticals, Inc.; Almirall, S.A; Naurex, Inc.; and Merck & Co. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Meury WilliamChief Commercial OfficerFeb 14Option Exercise63.1723,6131,491,73778,600Feb 16 05:10 PM
Meury WilliamChief Commercial OfficerFeb 14Sale160.6258,8799,457,36919,721Feb 16 05:10 PM
BODINE CHRIS WDirectorDec 07Buy164.773,030499,25317,098Dec 07 05:21 PM
SAUNDERS BRENT LChairman, President and CEODec 06Buy164.744,600757,794186,377Dec 06 12:31 PM
COUGHLIN CHRISTOPHER JDirectorDec 05Buy163.3010,0001,633,00014,446Dec 05 04:16 PM
Meury WilliamChief Commercial OfficerDec 01Option Exercise78.8811,807931,33668,828Dec 04 06:21 PM
Meury WilliamChief Commercial OfficerDec 01Sale173.8911,8072,053,11957,021Dec 04 06:21 PM
SAUNDERS BRENT LChairman, President and CEOJun 16Buy235.964410,327131,178Sep 18 08:49 PM
Basgoz NesliDirectorMay 18Option Exercise84.441,889159,5077,919May 22 04:26 PM
Basgoz NesliDirectorMay 18Sale220.451,889416,4306,030May 22 04:26 PM
GALLAGHER MICHAEL RDirectorMay 04Option Exercise245.2517,6934,339,20820,272May 05 06:34 PM
SAUNDERS BRENT LChairman, President and CEOMar 29Buy242.214310,299131,135Sep 18 08:49 PM
BISARO PAULDirectorMar 02Sale246.6870,00017,267,561235,900Mar 06 06:59 AM